A platform utilizing Drosophila ovulation for nonhormonal contraceptive screening

Area of Science:

• Reproductive biology and pharmacology
• Development of novel nonsteroidal contraceptives

Background:

• Significant unmet need for new contraceptive options due to side effects and inconvenience of current methods.
• Development of novel nonsteroidal female contraceptives has been hindered by a lack of effective screening platforms.

Purpose of the Study:

• To explore the potential of using *Drosophila* (fruit fly) as a model to screen for nonsteroidal contraceptive candidates.
• To identify compounds that inhibit follicle rupture, a crucial step in ovulation.

Main Methods:

• Screened 1,172 Food and Drug Administration (FDA)-approved drugs using an ex vivo *Drosophila* follicle rupture assay.
• Characterized the molecular mechanisms of identified drugs, focusing on adrenergic signaling.
• Validated drug efficacy in inhibiting mouse follicle rupture in vitro and in vivo, assessing effects on progesterone production.

Main Results:

• Identified six FDA-approved drugs that inhibit *Drosophila* follicle rupture in a dose-dependent manner.
• Three of four validated drugs inhibited mouse follicle rupture in vitro; two did not affect progesterone production.
• Chlorpromazine demonstrated significant inhibition of mouse follicle rupture in vivo.

Conclusions:

• *Drosophila* ovulation serves as a valuable screening platform for identifying nonsteroidal contraceptive lead compounds.
• FDA-approved drugs show potential as novel nonsteroidal contraceptive agents, addressing a critical unmet need.